BioMagnetic Solutions, LLC Management Team:
Paul A. Liberti, CEO and Chief Scientific Officer
Columbia College; Stritch School of Medicine; Stevens Institute of Technology; post-doctoral: NJ College of Medicine/Jefferson Medical College (Immunochemistry); National Institute for Medical Research, Mill Hill London (Cellular and Viral Immunology); was on the faculty of Jefferson Medical College for 16 years, rising from Assistant Professor to Full Professor in 5 years. A recipient of an NIH Career Development Award, he built a substantial National Institute of Health funded research program and was Director of an Immunology Post-Doctoral Training Program funded by the National Institute for Allergy and Infectious Diseases. He was a principal speaker at several international symposia having achieved recognition for his work on the structure of antibody combing sites and on studies regarding of the role (if any) of antibody conformational changes induced by reaction with germs as well as subsequent reactions with the Complement system following antibody recognition.
Following a successful academic career at Thomas Jefferson Medical College (Professor of Immunology/Physical Biochemistry), he founded (1983) and managed Immunicon Corp., a biotechnology firm based in Huntingdon Valley, PA for 16 years. In that period, he invented and developed: a broad spectrum of highly magnetic colloids for use in immunoassays and in cell diagnostics, novel high gradient quadrupole and hexapole separators as well as methods for immunoassays and cell isolation. He holds over 30 U.S. seminal patents in these areas. In addition to leading the R&D program, he played a key role in Business Development particularly in corporate partnering (in excess of $30MM with 5 major firms) and venture funding (completing three rounds) as well as the management and strategy of the company’s IP.
Based on his insights and discoveries on the exquisite ability of these systems to find “the needle in the haystack” as regards cells in complex systems, he steered Immunicon into rare cell analysis (cancer cells) and developed, with a substantial research team that he recruited, a platform cancer diagnostic technology he named “CellSearch®.”
Immunicon Corp. was acquired by Johnson & Johnson in 2008 who in 2003 built a new SBU around Immunicon’s CellSearch® technology and product suite, J&J’s Veridex division (now Janssen Diagnostics). In 2004, Immunicon was named Nanotechnology IPO of the Year by Small Times magazine. Immunicon raised over a $100MM in private venture funding prior to its NASDAQ IPO in 2004 when it raised $130MM.
In 2009, the CellSearch® Circulating Tumor Cell (CTC) Test was honored with the prestigious Prix Galien USA 2009 Award for Best Medical Technology. First awarded in the USA in 2009, the Prix Galien* recognizes the Best Medical, Biotechnology and Pharmaceutical Technology approved by the FDA in the past ten years. With over 8 Nobel Laureates on the 2009 Prix Galien’s committee, the Prix Galien is the Nobel Prize of the commercial medical and biotechnology fields.
Ted L. Liberti, COO & VP of Business Development
Ted started his career in international banking with JP Morgan Paris at the nexus of business, economics and his French language fluency. Later with Immunicon Corp., he played a key role with their French business development, contract research projects and collaborations with two major firms: bioMerieux and Guerbet as well as French academic groups in Paris and Lyon. He advised Immunicon on the valuation of Immunicon’s MRI contrast agent patent, leading to a $750,000 licensing arrangement with Sweden’s Nycomed Pharmaceuticals. From 2006 to 2012, he applied his marketing, economics, business development and strategy/due diligence capabilities to Ben Franklin Technology Partners’ portfolio of: life science, medical device and IT firms. From 2008 to 2011, Ted parlayed his entrepreneurial and managerial skills to co-founding, creating and growing the Penn State Wine Festival into an official PLCB festival, serving as co-founder, co-chair and the sole wine industry coordinator. He performed all key executive, marketing, business development and promotional roles with the wine industry and the PLCB’s marketing team.
Ted holds a B.S. in Economics and French from Penn State University and a M.A. in Applied Economics from the University of Delaware. Ted completed doctoral research in strategy, entrepreneurship, economics and social network theory at Penn State’s Smeal College of Business and Penn State’s Department of Economics. Ted also holds an M.B.A. in international corporate strategy from the University of Delaware with high honors.
* The Prix Galien USA committee judges which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.
Henry C. Wagner, III
Hank Wagner, B.S. Finance, WVU; MHA Duke; served as President and CEO of Jewish Hospital-University of Louisville, Kentucky for 32 years. There he grew the organization from a single medical center teaching hospital with revenues of $50 million to a regional network of 10 hospitals/outpatient centers/home care services with revenues of $1 billion. The organization pioneered 75 medical firsts in Kentucky to include the first open heart surgery, first heart transplant, first lung transplant, world’s first artificial heart implant, the first kidney transplant, first pancreatic transplant, first liver transplant, first reimplantation of a severed hand and the world’s first successful cadaveric hand transplant.
Wagner worked with Kentucky Governor Paul Patton and James Ramsey, President of the University of Louisville to establish the Kentucky “Bucks for Brains” Professorships. To date, over 75 endowed professorships have been created. Along with University of Louisville’s pioneer heart surgeon Laman Gray, M.D., Wagner created the Cardiovascular Innovation Institute which continues to be the major heart research center in Kentucky. For this vision and successful realization, Wagner was award an honorary PhD by the University of Louisville in 2010.
Active in Louisville’s civic and business efforts, Wagner served on the Boards of the University of Louisville Trustees; Kentucky Center for the Arts, the Chamber of Commerce and the Speed Art Museum. He also chaired the UofL Foundation; United Way; Fund for the Arts and Leadership of Louisville. He was founding chair for the Louisville Healthcare Enterprise Network. Wagner was hono University of Louisville red to be named to the Kentucky Business Hall of Fame, was named to the Kentucky Institute of Medicine, named YMCA Person of the Year and received the Thurgood Marshall Award of Excellence.
Wagner currently serves on the WVU Medical Center National Advisory Board. He also serves on the Board of Sullivan University in Louisville, KY and is a visiting professor for the University.
Michael J. Degenhart
Michael Degenhart is currently Executive Director of the Office of Gift Planning at Penn State University, where he is responsible for the development and implementation of university-wide planned giving efforts for 24 campuses with an overall combined gift planning goal of $70 million annually.
An entrepreneurial team builder and experienced advancement executive with an outstanding track record of success in leadership, fundraising, alumni relations and campaign management in both public and private institutions. Michael is a strategic thinker and effective communicator and is a key member of the campaign team for Penn State’s $2 billion dollar comprehensive campaign.
Michael has previously held senior advancement positions at Cornell and Syracuse Universities. Before pursuing a career in higher education advancement, Michael served as Vice President in the Private Client Group with Robert W. Baird & Co. working with successful entrepreneurs on investment strategies and capital access and transactions. He has been quoted in Bloomberg Wealth Manager, The Chronicle of Higher Education, The Chronicle of Philanthropy, and the Journal of Gift Planning. He has authored articles that have appeared in many publications, including Planned Giving Today and the Major Gift Report.
Michael received his bachelor’s degree in Economics from the University of Wisconsin, Madison and holds a Master of Business Administration from the University of Rochester’s Simon School of Business. He is also an Accredited Estate Planner and Certified Fund Raising Executive.
Thomas J. Momjian, Esq.
Tom is a partner with Coss & Momian, LLP in Bala Cynwyd, PA, a law firm focusing on securities industry disputes.
Tom graduated from Columbia Law School in 1992, where he was the Managing Editor of the Columbia Journal of Law and Social Problems. He obtained his B.A. from Columbia College in 1989 where he was elected to Phi Beta Kappa.
Civically, Tom has volunteered his time and expertise philanthropically to Armenian communities around the world through his involvement with the Armenian Missionary Association of America, Inc.